CRINETICS PHARMACEUTICALS is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. CRINETICS PHARMACEUTICALS is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | $1.04M |
| Net Income (Most Recent Fiscal Year) | $-298.41M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.37 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -43191.05% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -30.95% |
| Return on Assets (Trailing 12 Months) | -28.12% |
| Current Ratio (Most Recent Fiscal Quarter) | 22.53 |
| Quick Ratio (Most Recent Fiscal Quarter) | 22.53 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $14.29 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.04 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.69 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.82 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 93.63M |
| Free Float | 88.01M |
| Market Capitalization | $2.97B |
| Average Volume (Last 20 Days) | 0.71M |
| Beta (Past 60 Months) | 0.28 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.51% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |